Skip to content

Aesyra raises CHF 2.6 Million

Share this article

The Vaud-based and EPFL spin-off develops oral appliances preventing sleep bruxism and sleep apnea. The seed financing round was led by Supermoon Capital (USA), the world’s first fund focused on sleep technologies, and high-tech investor Creadd Ventures (Switzerland), with the participation of existing investor Zürcher Kantonalbank.



The new financing will support the development and commercialization of Aesyra’s AesyBite® range of products for the precise monitoring and treatment of sleep bruxism and sleep apnea. Sleep bruxism is a sleep disorder often associated with sleep apnea, affecting nearly a billion people worldwide. A company spun out of the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, Aesyra has invented a powerful technological system – combining a unique oral appliance, proprietary sensors and AI – that has demonstrated a reduction of over 70% in tooth grinding activity in users. Technology developed by EPFL researchers and algorithms leveraging over 10 years of sleep research data underpin Aesyra’s AesyBite™ solution.


“This important investment marks a crucial moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra. “We are delighted to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving significant change in the sleep sector. With their support, we are well positioned to accelerate the deployment of our revolutionary solutions, ultimately improving patient outcomes and advancing healthcare practices.”


“Aesyra’s sophisticated technology represents a major step forward in sleep science for the treatment of sleep bruxism and sleep apnea,” said Michael Masterson, Managing Partner of Supermoon Capital. “We are impressed by the company’s unique approach, strong management team and unwavering commitment to revolutionizing healthcare, and look forward to working closely with Aesyra to support its mission.”


“We chose Aesyra as Creadd Ventures’ first investment because the company fits perfectly with our philosophy of investing in companies that can potentially have a profound impact on patients’ quality of life,” said Lorenzo Leoni, founder and managing partner of Creadd Ventures.


Mr Masterson and Mr Leoni will join Aesyra’s Board of Directors, bringing their extensive industry expertise and strategic leadership to accelerate the company’s growth and success.



About Aesyra

Aesyra is a privately-held, clinical-stage company dedicated to the development, manufacture and commercialization of intelligent medical devices capable of accurately tracking and alleviating sleep bruxism and sleep apnea. The company has developed a range of devices (AesyBite®) using innovative, proprietary sensors and algorithms enabling intraoral measurements of several factors during sleep, and capable of actively reducing bruxism and improving patients’ quality of life.


Source: Aesyra